-
Can Betadine Gauze Compression Be Decreased Significant Complications after Prostate Needle Biopsy under Transrectal Ultrasound at Outpatient Department?: Single Clinician’s Experience
-
Hong Chung, Hong Sup Kim, Sang-Kuk Yang
-
Korean J Urogenit Tract Infect Inflamm 2012;7(1):43-49. Published online April 30, 2012
-
-
-
 Abstract
 PDF
- "Purpose: Recently, the number of patients undergoing prostate biopsy has increased due to the development of cancer screening test with prostate specific antigen. Prostate needle biopsy under transrectal ultrasound (Bx-TRUS) is the standard procedure to diagnose prostate cancer. We evaluated the incidence of significant infectious and bleeding complications performed by a single urologist with unique methods of betadine gauze compression after Bx-TRUS. Materials and Methods: We retrospectively evaluated the medical records of 299 patients, who underwent Bx-TRUS, from March 2007 to December 2011. All patients received oral levofloxacin 500mg for 4 days. Significant complications, related to infection with fever and persistent rectal bleeding, were evaluated within 4 weeks after biopsy. Patients who presented infectious complications were treated with intravenous ceftriaxone 2.0gm for 5 or 7 days. Patients who present significant anal bleeding were managed with primary closure by colorectal clinic in the department of surgery. Results: Among 299 patients, 4patients (1.3%) developed post-biopsy infections and hemorrhage. Those major complications were catergorized as acute prostatitis (2 patients, 0.7%) and rectal bleeding (2 patients, 0.7%). Of the 2 cases with post-biopsy infection, 1 case (Escherichia coli) had positive urine and blood culture. E. coli was sensitive to cephalosporine, but was resistant to fluoroquinolone. Conclusions: The results of this study suggest that betadine compression after Bx-TRUS may play the role of decreasing or preventing the significant complications, such as febrile infections and persistent rectal bleeding. Further, well designed study is needed to evaluate the clinical implication of betadine gauze compression after Bx-TRUS."
-
Percutaneous Management of Renal Abscess in Polycystic Kidney Disease
-
Hong Chung, Yong Ik Lee, Hong Sup Kim, Sang-Kuk Yang
-
Korean J Urogenit Tract Infect Inflamm 2011;6(2):209-212. Published online October 31, 2011
-
-
-
Abstract
PDF
- Autosomaldominant polycystic kidney disease (ADPKD) is one of the commonest hereditary disorders and the most common life-threatening genetic disease, affecting an estimated 12.5 million people worldwide. PKD are congenital and bilateral diseases, and those symptoms almost never appear until after age 40. Urinary tract infection occurs with increased frequency in ADPKD and infection in ADPKD is a particularly serious complication. Here, we report a 79-year-old man with an intermittent high fever during 2 months and bulging mass at the right flank.
-
Management of Genital Human Papillomavirus Infection
-
Sang-Kuk Yang
-
Korean J Urogenit Tract Infect Inflamm 2009;4(2):177-183. Published online October 31, 2009
-
-
-
Abstract
PDF
- More than 100 types of human papillomavirus (HPV) have been identified based on DNA homology, and more than 40 types of them can infect the anogenital area. HPV infections can cause genital warts, and high-risk genotypes are associated with penile and cervical cancer. The majority of HPV infections are asymptomatic, unrecognized, or subclinical. HPV high-risk genotype 16, 18, 35, 51, 58 are reported to the common causes of cervical cancer in Korea. Diagnosis of genital warts can be easily made by visual inspection, and the primary treatment goal is the removal of the warts. Although several treatment modalities for genital warts show similar effectiveness, 20∼50% of patients will experience recurrences of warts after therapy within 3-6 months. Although several well-designed studies have examined the association between male circumcision and HPV infection, results are still inconsistent. To date, the two first-generation vaccines (Gardasil?, Merck & Co., Inc., Whitehouse Station, USA; Cervarix?, GSK Biologicals, Belgium) have been used for prevention of cervical cancer, and both vaccines have been approved for use in women only, despite men being known to be the responsible vector. Currently there are no published data demonstrating that the vaccine can protect men from getting genital warts or HPV-related penile cancer. The increasing incidence of HPV infection and genital warts highlights the need for an clinical trials conducted in men to reveal the reduction rate of the HPV vaccines.
|
KAUTI
